Tag - ONCS

Markets

BTIG cuts OncoSec to neutral on updated Phase 2 results

BTIG downgraded OncoSec Medical (NASDAQ:ONCS) to “neutral” from “buy” and removed its price target after the company reported updated Phase 2 Keynote-695 study results. The stock closed at $4.66 on Nov. 11. Analyst...

November 14, 2022

Markets

BTIG starts OncoSec Medical at buy; PT $10

BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...

March 8, 2021

Markets

Dawson James starts OncoSec Medical at buy; PT $10

Dawson James Securities launched coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $3.19 on July 24. OncoSec has developed a plasmid-based vector that is delivered...

July 27, 2020

Developments

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...

December 13, 2019

Tag - ONCS

BTIG cuts OncoSec to neutral on updated Phase 2 results

BTIG starts OncoSec Medical at buy; PT $10

Dawson James starts OncoSec Medical at buy; PT $10

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

General

More